For the next 5‐10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB)
inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While
Food and Drug Administration (FDA)‐licensed units will be prioritized, it will always be
possible that an unlicensed unit will have known attributes, making it a better source of
cells for the given indication. Because of the wide variety of current and potential
indications as a source of cells for hematopoietic reconstitution or other form of cellular
therapy, it is critical that the investigators have access to unlicensed UCB units.